Prostate Cancer | Specialty

Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate Cancer

January 10th 2017

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Dr. Stein on Trials Investigating Biomarkers in Prostate Cancer

January 9th 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses trials investigating the use of circulating tumor cells as biomarkers for patients with prostate cancer.

Dr. Oh on the Safety Profile of Docetaxel in Prostate Cancer

January 6th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the safety profile of docetaxel when administered to patients with prostate cancer.

The Future of Biomarkers in Prostate Cancer

January 6th 2017

At this year’s Chemotherapy Symposium held in New York, a standout presentation by Mark Stein, MD, showed that there is a lot of promise in the area of circulating tumor cell biomarkers for patients with prostate cancer.

Dr. Twardowski on Steps Toward Optimal Sequencing for mCRPC Therapies

December 17th 2016

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.

Dual Androgen Blockade Ineffective After Enzalutamide in mCRPC

December 16th 2016

Adding enzalutamide to abiraterone acetate failed to improve progression-free survival versus abiraterone alone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide.

Expert Explains Evolving Role of Radium-223 in mCRPC

December 13th 2016

For patients with metastatic castration-resistant prostate cancer, the radiopharmaceutical radium-223 dichloride has proven to be an efficacious bone-targeted agent.

Patient-Friendly Policies Extend to Decision Making

December 12th 2016

It was not that long ago that decisions regarding cancer management were essentially made exclusively by the treating physician, with patients simply being informed of “the plan” for their treatment.

Prostate Cancer Screening & Early Detection

December 7th 2016

Genetic Testing and Prostate Cancer

December 7th 2016

Monitoring Patients During Treatment for Advanced Prostate Cancer

December 7th 2016

Age, Exercise, and ADT for Prostate Cancer

December 7th 2016

Androgen Deprivation Therapy for Prostate Cancer: Involving Primary Care

December 7th 2016

Shared Care in Prostate Cancer

December 7th 2016

Shared Decision Making for Prostate Cancer

December 7th 2016

Who to Screen: Finding the High-Risk Prostate Cancer Patient

December 7th 2016

DNA Repair Defects Emerge as a New Category for Anticancer Therapies

December 2nd 2016

A coordinated network of signaling pathways works to protect the cell from the toxic effects of DNA damage.

Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

December 2nd 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate Cancer

December 2nd 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.

Future of Genetic Testing and Treatment in Prostate Cancer

December 1st 2016